Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 5 ADC Manufacturing Challenges You Need To Know | Contract Pharma

What are you searching for?

Sign in
White Papers / Tech Papers

5 ADC Manufacturing Challenges You Need To Know

Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.

Released By Ajinomoto Bio-Pharma Services

The unique targeting capabilities and promising clinical trial results of antibody- drug conjugates (ADCs) have made them an exciting and promising treatment in the fight against cancer. According to recent analysis, experts anticipate the ADC market to be worth $10 billion annually by 2025. However, despite this tremendous growth, drugmakers still face a number of challenges in the manufacturing process for ADCs. Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.

DOWNLOAD TO LEARN MORE>>>>

Download White Papers / Tech Papers Now

Download White Papers / Tech Papers Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters